Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W6DY
|
|||
| Former ID |
DAP001071
|
|||
| Drug Name |
Diphenylpyraline
|
|||
| Synonyms |
Allergen; Belfene; Dafen; Dayfen; Diafen; Difenilpiralina; Diphenylpyralamine; Diphenylpyralinum; Diphenylpyrilene; Hispril; Histryl; Histyn; Hystryl; Lergobine; Lyssipoll; Mepiben; Neargal; AN 1041; Difenilpiralina [INN-Spanish]; Diphenylpyraline (INN); Diphenylpyraline [INN:BAN]; Diphenylpyralinum [INN-Latin];Diphenylpyraline maleate (2:1); N-Methylpiperidyl-(4)-benzhydrylaether salzsauren salze; N-Methylpiperidyl-(4)-benzhydrylaether salzsauren salze [German]; 1-Methyl-4-piperidyl benzhydryl ether; 1-methyl-4-hydroxypiperidine benzhydryl ether; 4-(Benzhydryloxy)-1-methylpiperidine; 4-(Diphenylmethoxy)-1-methylpiperidine; 4-(benzhydryloxy)-N-methylpiperidine; 4-DIPHENYLMETHOXY-1-METHYLPIPERIDINE; 4-[(diphenylmethyl)oxy]-1-methylpiperidine; 4-benzhydryloxy-1-methylpiperidine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Allergic rhinitis [ICD-11: CA08.0] | Approved | [1], [2] | |
| Therapeutic Class |
Antihistamines
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H23NO
|
|||
| Canonical SMILES |
CN1CCC(CC1)OC(C2=CC=CC=C2)C3=CC=CC=C3
|
|||
| InChI |
1S/C19H23NO/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-19H,12-15H2,1H3
|
|||
| InChIKey |
OWQUZNMMYNAXSL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 147-20-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
615228, 5046068, 8151975, 10508417, 11112289, 11336026, 11361265, 11363896, 11366458, 11369020, 11371242, 11374260, 11377182, 11455164, 11462237, 11466735, 11467855, 11484779, 11486550, 11488798, 11490217, 11492336, 11494816, 15442665, 29222246, 46504936, 47365245, 47365246, 47515368, 47736537, 47885465, 48185045, 48259283, 48334549, 48415912, 49698858, 50016255, 50123603, 50123604, 50938711, 57321610, 85171690, 85209863, 85788475, 92729772, 96024558, 99319623, 103555994, 103856536, 104098725
|
|||
| ChEBI ID |
CHEBI:59788
|
|||
| SuperDrug ATC ID |
R06AA07
|
|||
| SuperDrug CAS ID |
cas=000147206
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium ruminantium
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Diphenylpyraline can be metabolized by Bifidobacterium ruminantium (log2FC = -0.329; p = 0.014). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H1 receptor (H1R) | Target Info | Antagonist | [4] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | Histamine H1 receptor mediated signaling pathway | |||
| Reactome | Histamine receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| IL-4 Signaling Pathway | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7165). | |||
| REF 2 | Drug information of Diphenylpyraline, 2008. eduDrugs. | |||
| REF 3 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 4 | Transport mechanism of an H1-antagonist at the blood-brain barrier: transport mechanism of mepyramine using the carotid injection technique. Biol Pharm Bull. 1994 May;17(5):676-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.